Body weight loss as a prognostic/predictive factor in previously treated patients with metastatic gastric or gastroesophageal junction cancer: post hoc analyses of the phase III TAGS trial

Michele Ghidini,1 Howard Hochster,2 Toshihiko Doi,3 Eric Van Cutsem,4 Lukas Makris,5 Karim A. Benhadji,6 Wasat Mansoor7

1Azienda Ospedaliera di Cremona, Cremona, Italy; 2Rutgers Cancer Institute, New Brunswick, NJ; 3National Cancer Center Hospital East, Chiba, Japan; 4University Hospitals Gasthuisberg, Leuven, Belgium; 5Stathmi, Inc, New Hope, PA; 6Taiho Oncology, Inc., Princeton, NJ; 7The Christie NHS Foundation Trust, Manchester, UK